Listen to this article on the DDW Podcast: By Ori Zelichov MD, VP Clinical Development at Nucleai. Immunotherapies, namely immune checkpoint inhibitors (ICI), have revolutionised cancer treatment providing durable clinical benefits for patients with metastatic solid tumours. While ICIs are now considered a backbone treatment in many cancer types, only a small subset of patients (20-30%) […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!
